Reclast (Zoledronic Acid) Cost in Arizona 2026: Prices, Insurance, and Savings

Zoledronic acid is a bisphosphonate given as an intravenous infusion. Under the brand name Reclast, it is FDA-approved for osteoporosis (5 mg once yearly for treatment, once every two years for prevention) and for Paget's disease of bone. A different, higher-dose, more-frequent formulation of the same molecule is sold as Zometa for cancer-related bone conditions; that formulation and its pricing are outside the scope of this page. Generic zoledronic acid for osteoporosis has been FDA-approved and marketed since 2013.

The real cost question in Arizona is not "what does Reclast cost" but "which lever changes your price"

A single published cash price for Reclast in Arizona does not exist in any verifiable, dated, first-party source. What does exist, consistently, across pricing trackers and industry reporting, is a pattern: brand vs. generic status, infusion site (hospital outpatient department vs. physician office or independent infusion suite), and insurance pathway (commercial, Medicare Part B, AHCCCS, or cash) each move the price independently and by a larger margin than geography alone. A patient who only asks "what does it cost in Arizona" without asking about these three levers is likely to get an answer that does not reflect their actual bill.

What a Reclast or generic zoledronic acid infusion costs

Manufacturer list price for brand-name Reclast is commonly cited in the range of roughly $1,000-$1,500 per infusion, though list prices change and should be confirmed against a current source such as the manufacturer or a pharmacy benefit lookup rather than assumed from this page. Generic zoledronic acid is typically reported at a substantial discount to brand list price on cash-pay discount platforms, with figures in the $350-$900 range appearing depending on pharmacy and month. These are directional figures from secondary pricing sources, not verified Arizona-specific data, and they change over time.

Separate from the drug cost, the facility charges an administration fee for the IV infusion itself. Hospital outpatient departments generally bill more than independent infusion centers or physician offices for the same drug and the same 15-minute infusion, because facility fees are calculated differently in each setting. If cost is a concern, request an itemized quote from more than one infusion site that separates the drug acquisition cost from the facility/administration fee before scheduling.

Does Arizona Medicaid (AHCCCS) cover Reclast?

Arizona's Medicaid program, AHCCCS, has not historically covered Reclast or generic zoledronic acid for osteoporosis. Medicaid formularies are updated on their own schedule and this exclusion should be verified directly against the current AHCCCS preferred drug list rather than assumed to still be accurate at the time you are reading this.

Where zoledronic acid is not covered, oral bisphosphonates such as alendronate and risedronate are typically the covered alternatives on state Medicaid formularies, though they require weekly or monthly dosing rather than a single annual infusion. Adherence with oral bisphosphonates is well documented in the clinical literature to be lower than with once-yearly IV zoledronic acid, largely because oral bisphosphonates require strict administration instructions (empty stomach, remaining upright, waiting before eating) that many patients do not sustain long-term. A patient who has failed or cannot tolerate oral bisphosphonates due to gastrointestinal intolerance, esophageal disease, or inability to follow the dosing instructions is the typical candidate for a Medicaid prior-authorization exception request; documentation of the failed or contraindicated oral trial is generally what strengthens such an appeal, though AHCCCS's specific exception criteria should be confirmed with the plan.

How commercial insurance and Medicare Part B typically handle it

Because zoledronic acid is administered by a clinician in a clinical setting, it is billed under the medical benefit (not the retail pharmacy benefit) using a physician-administered drug billing code. This affects how cost-sharing is calculated: instead of a pharmacy copay, the patient typically owes coinsurance based on the allowed amount for the medical claim.

Medicare Part B covers zoledronic acid for osteoporosis when medical necessity criteria are met (generally a qualifying bone density result or a history of fragility fracture). Standard Part B cost-sharing applies: the patient is responsible for the annual Part B deductible and then 20% coinsurance on the Medicare-approved amount. The exact deductible and approved payment amount change annually and by drug-pricing quarter; readers should confirm the current figures at Medicare.gov or with their plan rather than rely on a number printed here.

For commercially insured Arizona patients, most major insurers require prior authorization for zoledronic acid, generally documented with a DXA scan and T-score, an osteoporosis or Paget's disease diagnosis, and sometimes a record of a prior oral bisphosphonate trial. Denials are more often tied to missing documentation than to a clinical rejection of the drug itself, but plan-specific requirements vary and should be confirmed with the individual insurer.

Generic vs. brand: does it matter clinically?

No. FDA-approved generic zoledronic acid must meet the same bioequivalence and manufacturing standards as brand-name Reclast, and the two are expected to perform identically. The FDA's Orange Book lists approved zoledronic acid products and their therapeutic equivalence ratings. Patients generally do not choose their manufacturer directly; the infusion site's stock determines which product is used. Asking whether a generic will be used, when one is available, is a reasonable cost question to raise with the prescriber or infusion center.

The HORIZON-PFT trial, a large randomized controlled study published in the New England Journal of Medicine in 2007, demonstrated that zoledronic acid reduced vertebral and hip fracture incidence in postmenopausal women with osteoporosis relative to placebo over a three-year period. These fracture risk reductions are frequently referenced across the medical literature; however, clinicians and readers requiring specific effect sizes and confidence intervals for treatment decisions should consult the original trial publication rather than relying on indirect citations, as the citation identifiers associated with this page have not been independently confirmed.

Compounded zoledronic acid: what it is and what it is not

Compounded zoledronic acid can be obtained in Arizona from a licensed 503A pharmacy, which prepares patient-specific prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounding this product should hold an active Arizona Board of Pharmacy license and follow USP 797 sterile compounding standards, since zoledronic acid is given intravenously.

Compounded drugs are not FDA-approved. They have not gone through the FDA's premarket review of manufacturing, potency, and sterility that applies to commercially manufactured generics and brand products. FDA guidance explains this distinction. Some patients and prescribers choose compounded zoledronic acid when cost is prohibitive or a commercial product is unavailable, but this is a judgment call that should involve the prescribing physician weighing quality-assurance tradeoffs against cost, not a default first choice when an FDA-approved generic is accessible.

Telehealth: what can and cannot happen remotely

An Arizona-licensed physician can conduct the initial consultation, review DXA and lab results, and prescribe zoledronic acid through a telehealth visit. The infusion itself cannot be done remotely; it requires an in-person visit to a licensed infusion center, physician's office, or hospital outpatient department, because it is an IV medication requiring monitoring during administration.

Arizona has telehealth coverage requirements affecting commercial insurers, though the specific statute and its current scope should be verified with a licensed insurance source rather than assumed from this page, since state telehealth laws are amended periodically. For patients in rural Arizona counties where osteoporosis specialists are scarce, a practical workflow is: local lab draw (serum calcium, creatinine/eGFR, vitamin D) before the visit, a telehealth consultation with a specialist, a prescription sent to a local infusion site, and telehealth follow-up after the infusion.

Discount and assistance pathways

Manufacturer patient assistance. Novartis has historically offered a patient assistance program for brand-name Reclast for eligible uninsured or underinsured patients; income and other eligibility criteria are set by the manufacturer and change over time. Details should be confirmed directly with the manufacturer, not assumed from a prior year's terms.

Manufacturer copay cards. Copay assistance cards for brand-name Reclast are generally available only to commercially insured patients and explicitly excluded for government insurance (Medicare, Medicaid, TRICARE, VA). The specific copay amount a card reduces a bill to depends on the current program terms, which should be checked at the time of use.

Pharmacy discount platforms. Cash-pay patients can compare prices for generic zoledronic acid across participating pharmacies using discount platforms; these prices fluctuate and are set by the platform and pharmacy, not by this article.

Site-of-care selection. Choosing an independent infusion center or physician's office over a hospital outpatient department is one of the more consistently cited ways to reduce the facility-fee portion of the bill, though the magnitude of savings varies by facility and insurer contract.

340B pricing. Federally qualified health centers and disproportionate-share hospitals participating in the 340B Drug Pricing Program purchase outpatient drugs, including zoledronic acid, at reduced acquisition cost. Whether that discount is passed through to an individual patient's bill depends on the facility's billing practices and is not guaranteed.

Verification checklist: stable facts vs. facts that expire

Use this before acting on any cost or coverage claim about Reclast or zoledronic acid in Arizona, including the claims on this page.

Stable, unlikely to change year to year (federal regulatory and clinical facts):

• Zoledronic acid's FDA-approved indications for Reclast (osteoporosis treatment/prevention, Paget's disease), verify at accessdata.fda.gov
• Generic zoledronic acid's bioequivalence standard to brand Reclast, verify in the FDA Orange Book
• The distinction between Reclast (osteoporosis dosing) and Zometa (oncology dosing) as different products of the same molecule
• Contraindications such as severe renal impairment and hypocalcemia (confirm exact thresholds with the current FDA label, not this page)
• That compounded zoledronic acid is not FDA-approved and requires a 503A-licensed pharmacy

Date-sensitive, must be re-verified before relying on it (insurer, state, pharmacy, and cash-price facts):

• Whether AHCCCS currently covers zoledronic acid for osteoporosis, check the current AHCCCS preferred drug list
• The current Medicare Part B annual deductible and coinsurance amount, check Medicare.gov
• Whether your specific commercial plan requires prior authorization, and its current documentation requirements
• Current cash-pay price at a specific Arizona pharmacy or infusion center, call and request an itemized quote
• Whether the manufacturer copay card and patient assistance program terms you are relying on are still in effect
• Arizona's current telehealth parity requirements for the specific insurer involved

What is established, what is plausible, and what is not established

Established: Zoledronic acid is FDA-approved for osteoporosis at the Reclast dose and schedule; generic zoledronic acid is bioequivalent to brand Reclast; a large randomized trial (HORIZON-PFT) found fracture-risk reduction with once-yearly IV zoledronic acid compared with placebo in postmenopausal women; the infusion must be administered in a clinical setting where it can be monitored; compounded zoledronic acid is not FDA-approved.

Plausible but not confirmed by a first-party Arizona source in this article: The specific cash-pay price ranges, the specific dollar amount AHCCCS or commercial plans currently reimburse, and the exact statutory citation for Arizona's telehealth parity rule. These are the kind of claims that change by year and by plan, and none of the pricing figures in circulation for this drug in Arizona should be treated as a quote you can act on without confirming it with the payer or pharmacy directly.

Not established on this page: Any individualized recommendation about whether a specific patient should choose an oral bisphosphonate, IV zoledronic acid, or a compounded product, and any specific dosing decision. That determination depends on renal function, calcium and vitamin D status, fracture history, and other individual factors that only a treating clinician can evaluate.